시장보고서
상품코드
2117023

표적 방사성의약품 시장 : 제품 유형별, 용도별, 최종사용자별, 국가별, 지역별 - 세계 산업 분석, 시장 규모, 시장 점유율 및 예측(2026-2033년)

Targeted Radiopharmaceutical Market, By Product Type, By Application, By End User, By Country, and By Region - Global Industry Analysis, Market Size, Market Share & Forecast from 2026-2033

발행일: | 리서치사: 구분자 AnalystView Market Insights | 페이지 정보: 영문 361 Pages | 배송안내 : 2-3일 (영업일 기준)

    
    
    




가격
PDF (Single User License) help
PDF 보고서를 1명만 이용할 수 있는 라이선스입니다. 인쇄 불가능하며, 텍스트의 Copy&Paste도 불가능합니다.
US $ 3,250 금액 안내 화살표 ₩ 4,538,000
PDF (5 User License) help
PDF 보고서를 동일 사업장에서 5명까지 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.
US $ 4,560 금액 안내 화살표 ₩ 6,367,000
PDF & Excel (Enterprise User License) help
PDF & Excel 보고서를 동일 기업 내 모든 사용자가 사용할 수 있는 라이선스입니다. 텍스트의 Copy&Paste 가능합니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.
US $ 5,650 금액 안내 화살표 ₩ 7,889,000
※ 부가세 별도
한글목차
영문목차
※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

표적 방사성의약품 시장 규모는 2025년에 51억 870만 달러로 평가되며, 2026년부터 2033년까지 CAGR 10.9%로 확대될 것으로 전망됩니다.

표적 방사성의약품은 특정 조직을 표적으로 하는 분자에 방사성동위원소를 결합시킨 것으로, 정밀 의학의 특별한 범주에 속합니다. 표적 방사성의약품 시장은 진단용 PET 및 SPECT 제제, 치료용 방사성 리간드, 방사성 핵종 전구체, 발생 장치, 방사성 표지 장치, 그리고 위탁 제조 및 관리 서비스로 구성되어 있습니다. 주요 적용 분야는 종양학, 특히 전립선암 및 신경내분비종양이지만, 순환기학 및 신경학 분야에서도 중요한 용도가 있습니다. 한편, 많은 동위원소는 반감기가 짧기 때문에 그 제조, 무균 보관, 운송 및 의료기기는 공급망에서 중요한 요소로 작용하고 있습니다. 2025년, 미국 병원에서는 진단 시술에 매일 약 4만 회 분량의 Mo-99 동위원소가 사용되었습니다. 따라서 동위원소 공급은 표적 방사성의약품에서 지극히 중요한 역할을 수행하며, 새로운 분자 및 세포 표적 개발 수요를 보완함으로써 큰 경쟁 우위를 점하고 있습니다.

표적 방사성의약품 시장 - 시장 역학

테라노스틱스가 정밀 치료의 길을 재구축하고 있습니다

분자 영상과 표적 치료의 결합을 통해 정밀 종양학에 대한 보다 통합적인 접근이 진행되고 있습니다. 테라노스틱스 플랫폼은 진단용 영상 기술을 활용하여 종양에서 특정 표적을 발현하는 환자를 식별한 후, 동일한 수용체를 특이적으로 표적하는 테라노스틱스 제제를 사용하여 해당 환자를 치료하도록 설계되었습니다. 이처럼 이러한 접근법의 개발은 동반진단, 동위원소 공급망, 방사화학 인프라, 선량 측정 및 전문 치료 센터에 대한 수요를 견인하고 있습니다. 2025년 3월, FDA는 안드로겐 수용체 경로 억제제 투여 이력이 있는 PSMA 양성 전이성 거세저항성 전립선암 환자에 대한 ‘Pluvicto’의 사용을 승인했습니다. 또한, ‘PSMAfore’ 임상시험에서는 대조군 치료에 비해 영상상 진행 또는 사망 위험이 59% 감소한 것으로 확인되어, 분자 수준에서 유도된 방사성 리간드 치료의 조기 도입에 대한 근거가 더욱 강화되었으며, 이는 테라노스틱스 시장의 성장을 뒷받침하고 있습니다.

표적 방사성의약품 시장 - 지역별 분석

북미는 제약 기업, 생명공학 개발 기업, 학술적 핵의학 센터, 국가 동위원소 프로그램 및 전문 제조 시설로 구성된 견고한 네트워크를 바탕으로 방사성의약품 시장의 선두를 차지하고 있습니다. 방사성의약품 시장은 반감기가 짧은 동위원소의 안정적인 공급에 크게 의존하고 있어, 지연, 공급 중단, 재고 관리상의 실수에 대한 허용 범위는 제한적입니다. 이 지역 전체의 정책 입안자와 제약 기업들은 의료용 동위원소의 공급이 중단되지 않도록 국내 동위원소 생산능력 및 방사성 리간드 제조 능력 확충을 최우선 과제로 삼고 있습니다. 2025년 현재, 미국에서는 하루 4만 회분의 Mo-99 진단용 투여량이 생산되고 있으며, 이는 해당 지역에서 핵의학의 보급도가 높음을 입증합니다. 따라서 북미는 전 세계 핵의학의 발전으로부터 혜택을 누리는 데 있어 견고한 입지를 차지하고 있을 뿐만 아니라, 새로운 치료제 개발을 견인하는 원동력이기도 합니다.

유럽의 표적 방사성의약품 시장은 기존의 핵의학 인프라, 제약 분야의 전문 지식, 연구 시설 및 규제에 의해 뒷받침되고 있습니다. 또한, 해당 지역에서는 방사성의약품의 생산과 유통에 대한 일원화된 관리가 이루어지지 않고 있어 공급망이 매우 중요합니다. 게다가 동위원소 사용에는 시간적 제약이 있기 때문에 효율적인 유통 네트워크가 요구됩니다. 예를 들어, 2025년 4월에는 유럽의약품청(EMA) 및 각국의 의약품 규제 당국 수장들이 EU 내 방사성의약품 공급 상황에 관한 권고안을 발표했습니다. 이는 규제 조화, 높은 의약품 생산능력, 그리고 다각적인 차원에서의 적극적인 대책을 통해 해당 지역이 이러한 위기를 관리하고 대응하기 위한 최상의 조건을 갖추고 있음을 보여줍니다.

목차

제1장 표적 방사성의약품 시장 개요

제2장 주요 요약

제3장 표적 방사성의약품 주요 시장 동향

제4장 표적 방사성의약품 산업 분석

제5장 표적 방사성의약품 시장 : 높아지는 지정학적 긴장의 영향

제6장 표적 방사성의약품 시장 구도

제7장 표적 방사성의약품 시장 : 제품 유형별

제8장 표적 방사성의약품 시장 : 용도별

제9장 표적 방사성의약품 시장 : 최종사용자별

제10장 표적 방사성의약품 시장 : 지역별

제11장 주요 벤더 분석 : 표적 방사성의약품 산업

제12장 AnalystView의 전방위 전망

KSM

Targeted Radiopharmaceutical Market size was valued at US$ 5,108.7 Million in 2025, expanding at a CAGR of 10.9% from 2026 to 2033.

Targeted radiopharmaceuticals represent a special category of precision medicines that involve attaching a radioactive isotope to molecules that specifically target certain tissues. The targeted radiopharmaceuticals market consists of diagnostic PET and SPECT agents, therapeutic radioligands, radionuclide precursors, generators, radiolabeling equipment, and contract manufacturing and control services. The main area of application is oncology, primarily prostate cancer and neuroendocrine tumors, but there are also significant applications in cardiology and neurology. At the same time, the short half-lives of many isotopes mean that their production, sterile storage, transportation, and medical equipment are important aspects of the supply chain. In 2025, U.S. hospitals used approximately 40,000 doses of the isotope Mo-99 every day in diagnostic procedures. Therefore, the availability of isotopes plays an essential role in targeted radiopharmaceuticals, complementing the need to develop new molecules and cell targets, and is a major competitive advantage.

Targeted Radiopharmaceutical Market- Market Dynamics

Theranostics Is Reshaping Precision Treatment Pathways

The combination of molecular imaging and targeted therapy is leading to a more integrated approach to precision oncology. Theranostic platforms are designed to utilize diagnostic imaging to identify patients with tumor expression of a given target and then treat those patients with a theranostic agent that specifically targets the same receptor. As such, the development of these approaches is driving need for companion diagnostics, isotope supply chains, radiochemistry infrastructure, dosimetry, and specialized treatment centers. In March 2025, the FDA approved Pluvicto for use in patients with PSMA-positive metastatic castration-resistant prostate cancer who had received an androgen-receptor pathway inhibitor, and the PSMAfore trial saw a 59% reduction in the risk of radiographic progression or death from the control treatment, further bolstering the case for earlier molecularly guided radioligand treatment and supporting the growth of the theranostics market.

Targeted Radiopharmaceutical Market- Geographical Insights

North America is the leading radiopharmaceuticals market due to the strong network of pharmaceutical companies, biotech developers, academic nuclear-medicine centers, national isotope programs, and specialized manufacturing facilities. The radiopharmaceuticals market is highly dependent on the stable supply of short-lived isotopes, offers limited scope for delays, disruptions, and inventory management errors. Policymakers and pharmaceutical companies throughout the region are prioritizing the development of domestic isotope production capabilities and radioligand manufacturing to ensure an uninterrupted supply of medical isotopes. As of 2025, there are 40000 Mo-99 diagnostic doses produced daily in the US, which underlines the level of nuclear medicine adoption in the region. North America is therefore strongly positioned to benefit from the worldwide in nuclear medicine while also being the driving force behind the development of novel therapeutics.

Europe's targeted radiopharmaceutical landscape is supported by the existing nuclear-medicine infrastructure, pharma expertise, research facilities, and regulations. The region also lacks centralized control over radiopharmaceutical production and distribution, meaning the supply chain is of utmost importance. Moreover, time constraints for isotope use require efficient distribution networks. For example, in April 2025, the European Medicines Agency and Heads of Medicines Agencies released recommendations concerning the radiopharmaceutical supply situation in the EU. This shows that the region has the best conditions to manage and respond to such crises because of the harmonization of regulations, high pharma production capabilities, and proactive measures at multiple levels.

Targeted Radiopharmaceutical Market- Competitive Landscape:

Competition in targeted radiopharmaceuticals market is now focusing on broader areas from target discovery, access to radionuclides, radiochemistry, manufacturing, and clinical development to distribution. Thus, Novartis has developed a comprehensive radioligand platform, while competitors, including Bayer, Lantheus, Curium, and new biotech companies, are positioning themselves to provide diverse products and technologies in therapeutics, diagnostics, manufacturing, and specific areas of radiochemistry. Moreover, the overall capacity of production is critical, as radiopharmaceutical requires a stable and reliable supply chain that produces medicines with a short shelf life. Therefore, Novartis opened its third U.S. radioligand manufacturing facility in the Los Angeles area in November 2025. Hence, the ability to deliver complex radioligands to the clinic reliably allows Novartis to differentiate itself from competitors and provide a consistent supply of medicinal products for clinical partners and patients worldwide.

Recent Developments:

March 2025, Novartis: The U.S. FDA expanded the indication of Pluvicto for patients with PSMA-positive metastatic castration-resistant prostate cancer who had received androgen-receptor pathway inhibitor therapy and were treatment-naive in the second-line setting. The new indication moved radioligand therapy to an earlier treatment paradigm and extended the indication to a broader patient population.

In November 2025, Novartis opened a new 10,000-square-foot radioligand manufacturing facility in Carlsbad, California. This new U.S. radioligand production site is the company's third in the U.S. The new facility will help meet the needs of manufacturing these complex therapies while supporting the time-sensitive nature of radiolabeled compounds

SCOPE OF THE REPORT

The scope of this report covers the market by its major segments, which include as follows:

GLOBAL TARGETED RADIOPHARMACEUTICAL MARKET KEY PLAYERS- DETAILED COMPETITIVE INSIGHTS

  • Novartis AG
  • Lantheus Holdings, Inc.
  • Curium Pharma
  • GE HealthCare
  • Bayer AG
  • AstraZeneca plc
  • Eli Lilly and Company
  • Bristol Myers Squibb
  • ITM Isotope Technologies Munich SE
  • Telix Pharmaceuticals Limited
  • Bracco Imaging S.p.A.
  • Clarity Pharmaceuticals Ltd.
  • Eckert & Ziegler SE
  • Actinium Pharmaceuticals, Inc.
  • Evergreen Theragnostics, Inc.
  • Siemens Healthineers AG
  • Cardinal Health, Inc.
  • Boehringer Ingelheim International GmbH
  • Perspective Therapeutics, Inc.
  • RadioMedix, Inc.
  • NorthStar Medical Radioisotopes
  • Others

GLOBAL TARGETED RADIOPHARMACEUTICAL MARKET, BY PRODUCT TYPE- MARKET ANALYSIS, 2020 - 2033

  • Diagnostic Radiopharmaceuticals
  • PET Radiopharmaceuticals
  • SPECT Radiopharmaceuticals
  • Therapeutic Radiopharmaceuticals
  • Beta-Emitting
  • Alpha-Emitting
  • Others

GLOBAL TARGETED RADIOPHARMACEUTICAL MARKET, BY APPLICATION- MARKET ANALYSIS, 2020 - 2033

  • Oncology
  • Cardiology
  • Neurology
  • Endocrinology / Thyroid
  • Others

GLOBAL TARGETED RADIOPHARMACEUTICAL MARKET, BY END USER- MARKET ANALYSIS, 2020 - 2033

  • Hospitals & Clinics
  • Diagnostic Imaging Centers
  • Nuclear Medicine Centers
  • Cancer Treatment Centers
  • Academic & Research Institutes
  • Others

GLOBAL TARGETED RADIOPHARMACEUTICAL MARKET, BY REGION- MARKET ANALYSIS, 2020 - 2033

  • North America
  • U.S.
  • Canada
  • Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • The Netherlands
  • Sweden
  • Russia
  • Poland
  • Denmark
  • Rest of Europe
  • Asia Pacific
  • China
  • India
  • Japan
  • South Korea
  • Australia
  • Indonesia
  • Thailand
  • Philippines
  • Taiwan
  • Vietnam
  • Rest of APAC
  • Latin America
  • Brazil
  • Mexico
  • Argentina
  • Colombia
  • Rest of LATAM
  • The Middle East and Africa
  • Saudi Arabia
  • UAE
  • Israel
  • Turkey
  • Algeria
  • Egypt
  • Iran
  • Qatar
  • Rest of MEA

Table of Contents

1. Targeted Radiopharmaceutical Market Overview

  • 1.1. Study Scope
  • 1.2. Market Estimation Years

2. Executive Summary

  • 2.1. Market Snippet
    • 2.1.1. Targeted Radiopharmaceutical Market Snippet by Product Type
    • 2.1.2. Targeted Radiopharmaceutical Market Snippet by Application
    • 2.1.3. Targeted Radiopharmaceutical Market Snippet by End User
    • 2.1.4. Targeted Radiopharmaceutical Market Snippet by Country
    • 2.1.5. Targeted Radiopharmaceutical Market Snippet by Region
  • 2.2. Competitive Insights

3. Targeted Radiopharmaceutical Key Market Trends

  • 3.1. Targeted Radiopharmaceutical Market Drivers
    • 3.1.1. Impact Analysis of Market Drivers
  • 3.2. Targeted Radiopharmaceutical Market Restraints
    • 3.2.1. Impact Analysis of Market Restraints
  • 3.3. Targeted Radiopharmaceutical Market Opportunities
  • 3.4. Targeted Radiopharmaceutical Market Future Trends

4. Targeted Radiopharmaceutical Industry Study

  • 4.1. PEST Analysis
  • 4.2. Porter's Five Forces Analysis
  • 4.3. Growth Prospect Mapping
  • 4.4. Regulatory Framework Analysis

5. Targeted Radiopharmaceutical Market: Impact of Escalating Geopolitical Tensions

  • 5.1. Impact of COVID-19 Pandemic
  • 5.2. Impact of Russia-Ukraine War
  • 5.3. Impact of Middle East Conflicts

6. Targeted Radiopharmaceutical Market Landscape

  • 6.1. Targeted Radiopharmaceutical Market Share Analysis, 2025
  • 6.2. Breakdown Data, by Key Manufacturer
    • 6.2.1. Established Players' Analysis
    • 6.2.2. Emerging Players' Analysis

7. Targeted Radiopharmaceutical Market - By Product Type

  • 7.1. Overview
    • 7.1.1. Segment Share Analysis, By Product Type, 2025 & 2033 (%)
    • 7.1.2. Diagnostic Radiopharmaceuticals
      • 7.1.2.1. PET Radiopharmaceuticals
      • 7.1.2.2. SPECT Radiopharmaceuticals
    • 7.1.3. Therapeutic Radiopharmaceuticals
      • 7.1.3.1. Beta-Emitting
      • 7.1.3.2. Alpha-Emitting
      • 7.1.3.3. Others

8. Targeted Radiopharmaceutical Market - By Application

  • 8.1. Overview
    • 8.1.1. Segment Share Analysis, By Application, 2025 & 2033 (%)
    • 8.1.2. Oncology
    • 8.1.3. Cardiology
    • 8.1.4. Neurology
    • 8.1.5. Endocrinology / Thyroid
    • 8.1.6. Others

9. Targeted Radiopharmaceutical Market - By End User

  • 9.1. Overview
    • 9.1.1. Segment Share Analysis, By End User, 2025 & 2033 (%)
    • 9.1.2. Hospitals & Clinics
    • 9.1.3. Diagnostic Imaging Centers
    • 9.1.4. Nuclear Medicine Centers
    • 9.1.5. Cancer Treatment Centers
    • 9.1.6. Academic & Research Institutes
    • 9.1.7. Others

10. Targeted Radiopharmaceutical Market- By Geography

  • 10.1. Introduction
    • 10.1.1. Segment Share Analysis, By Geography, 2025 & 2033 (%)
  • 10.2. North America
    • 10.2.1. Overview
    • 10.2.2. Targeted Radiopharmaceutical Key Manufacturers in North America
    • 10.2.3. North America Market Size and Forecast, By Country, 2020 - 2033 (US$ Million)
    • 10.2.4. North America Market Size and Forecast, By Product Type, 2020 - 2033 (US$ Million)
    • 10.2.5. North America Market Size and Forecast, By Application, 2020 - 2033 (US$ Million)
    • 10.2.6. North America Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
    • 10.2.7. U.S.
      • 10.2.7.1. Overview
      • 10.2.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 10.2.7.3. U.S. Market Size and Forecast, By Product Type, 2020 - 2033 (US$ Million)
      • 10.2.7.4. U.S. Market Size and Forecast, By Application, 2020 - 2033 (US$ Million)
      • 10.2.7.5. U.S. Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
    • 10.2.8. Canada
      • 10.2.8.1. Overview
      • 10.2.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 10.2.8.3. Canada Market Size and Forecast, By Product Type, 2020 - 2033 (US$ Million)
      • 10.2.8.4. Canada Market Size and Forecast, By Application, 2020 - 2033 (US$ Million)
      • 10.2.8.5. Canada Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
  • 10.3. Europe
    • 10.3.1. Overview
    • 10.3.2. Targeted Radiopharmaceutical Key Manufacturers in Europe
    • 10.3.3. Europe Market Size and Forecast, By Country, 2020 - 2033 (US$ Million)
    • 10.3.4. Europe Market Size and Forecast, By Product Type, 2020 - 2033 (US$ Million)
    • 10.3.5. Europe Market Size and Forecast, By Application, 2020 - 2033 (US$ Million)
    • 10.3.6. Europe Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
    • 10.3.7. Germany
      • 10.3.7.1. Overview
      • 10.3.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 10.3.7.3. Germany Market Size and Forecast, By Product Type, 2020 - 2033 (US$ Million)
      • 10.3.7.4. Germany Market Size and Forecast, By Application, 2020 - 2033 (US$ Million)
      • 10.3.7.5. Germany Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
    • 10.3.8. UK
      • 10.3.8.1. Overview
      • 10.3.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 10.3.8.3. UK Market Size and Forecast, By Product Type, 2020 - 2033 (US$ Million)
      • 10.3.8.4. UK Market Size and Forecast, By Application, 2020 - 2033 (US$ Million)
      • 10.3.8.5. UK Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
    • 10.3.9. France
      • 10.3.9.1. Overview
      • 10.3.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 10.3.9.3. France Market Size and Forecast, By Product Type, 2020 - 2033 (US$ Million)
      • 10.3.9.4. France Market Size and Forecast, By Application, 2020 - 2033 (US$ Million)
      • 10.3.9.5. France Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
    • 10.3.10. Italy
      • 10.3.10.1. Overview
      • 10.3.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 10.3.10.3. Italy Market Size and Forecast, By Product Type, 2020 - 2033 (US$ Million)
      • 10.3.10.4. Italy Market Size and Forecast, By Application, 2020 - 2033 (US$ Million)
      • 10.3.10.5. Italy Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
    • 10.3.11. Spain
      • 10.3.11.1. Overview
      • 10.3.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 10.3.11.3. Spain Market Size and Forecast, By Product Type, 2020 - 2033 (US$ Million)
      • 10.3.11.4. Spain Market Size and Forecast, By Application, 2020 - 2033 (US$ Million)
      • 10.3.11.5. Spain Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
    • 10.3.12. The Netherlands
      • 10.3.12.1. Overview
      • 10.3.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 10.3.12.3. The Netherlands Market Size and Forecast, By Product Type, 2020 - 2033 (US$ Million)
      • 10.3.12.4. The Netherlands Market Size and Forecast, By Application, 2020 - 2033 (US$ Million)
      • 10.3.12.5. The Netherlands Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
    • 10.3.13. Sweden
      • 10.3.13.1. Overview
      • 10.3.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 10.3.13.3. Sweden Market Size and Forecast, By Product Type, 2020 - 2033 (US$ Million)
      • 10.3.13.4. Sweden Market Size and Forecast, By Application, 2020 - 2033 (US$ Million)
      • 10.3.13.5. Sweden Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
    • 10.3.14. Russia
      • 10.3.14.1. Overview
      • 10.3.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 10.3.14.3. Russia Market Size and Forecast, By Product Type, 2020 - 2033 (US$ Million)
      • 10.3.14.4. Russia Market Size and Forecast, By Application, 2020 - 2033 (US$ Million)
      • 10.3.14.5. Russia Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
    • 10.3.15. Poland
      • 10.3.15.1. Overview
      • 10.3.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 10.3.15.3. Poland Market Size and Forecast, By Product Type, 2020 - 2033 (US$ Million)
      • 10.3.15.4. Poland Market Size and Forecast, By Application, 2020 - 2033 (US$ Million)
      • 10.3.15.5. Poland Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
    • 10.3.16. Denmark
      • 10.3.16.1. Overview
      • 10.3.16.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 10.3.16.3. Denmark Market Size and Forecast, By Product Type, 2020 - 2033 (US$ Million)
      • 10.3.16.4. Denmark Market Size and Forecast, By Application, 2020 - 2033 (US$ Million)
      • 10.3.16.5. Denmark Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
    • 10.3.17. Rest of Europe
      • 10.3.17.1. Overview
      • 10.3.17.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 10.3.17.3. Rest of the Europe Market Size and Forecast, By Product Type, 2020 - 2033 (US$ Million)
      • 10.3.17.4. Rest of the Europe Market Size and Forecast, By Application, 2020 - 2033 (US$ Million)
      • 10.3.17.5. Rest of the Europe Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
  • 10.4. Asia Pacific (APAC)
    • 10.4.1. Overview
    • 10.4.2. Targeted Radiopharmaceutical Key Manufacturers in Asia Pacific
    • 10.4.3. APAC Market Size and Forecast, By Country, 2020 - 2033 (US$ Million)
    • 10.4.4. APAC Market Size and Forecast, By Product Type, 2020 - 2033 (US$ Million)
    • 10.4.5. APAC Market Size and Forecast, By Application, 2020 - 2033 (US$ Million)
    • 10.4.6. APAC Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
    • 10.4.7. China
      • 10.4.7.1. Overview
      • 10.4.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 10.4.7.3. China Market Size and Forecast, By Product Type, 2020 - 2033 (US$ Million)
      • 10.4.7.4. China Market Size and Forecast, By Application, 2020 - 2033 (US$ Million)
      • 10.4.7.5. China Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
    • 10.4.8. India
      • 10.4.8.1. Overview
      • 10.4.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 10.4.8.3. India Market Size and Forecast, By Product Type, 2020 - 2033 (US$ Million)
      • 10.4.8.4. India Market Size and Forecast, By Application, 2020 - 2033 (US$ Million)
      • 10.4.8.5. India Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
    • 10.4.9. Japan
      • 10.4.9.1. Overview
      • 10.4.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 10.4.9.3. Japan Market Size and Forecast, By Product Type, 2020 - 2033 (US$ Million)
      • 10.4.9.4. Japan Market Size and Forecast, By Application, 2020 - 2033 (US$ Million)
      • 10.4.9.5. Japan Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
    • 10.4.10. South Korea
      • 10.4.10.1. Overview
      • 10.4.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 10.4.10.3. South Korea Market Size and Forecast, By Product Type, 2020 - 2033 (US$ Million)
      • 10.4.10.4. South Korea Market Size and Forecast, By Application, 2020 - 2033 (US$ Million)
      • 10.4.10.5. South Korea Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
    • 10.4.11. Australia
      • 10.4.11.1. Overview
      • 10.4.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 10.4.11.3. Australia Market Size and Forecast, By Product Type, 2020 - 2033 (US$ Million)
      • 10.4.11.4. Australia Market Size and Forecast, By Application, 2020 - 2033 (US$ Million)
      • 10.4.11.5. Australia Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
    • 10.4.12. Indonesia
      • 10.4.12.1. Overview
      • 10.4.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 10.4.12.3. Indonesia Market Size and Forecast, By Product Type, 2020 - 2033 (US$ Million)
      • 10.4.12.4. Indonesia Market Size and Forecast, By Application, 2020 - 2033 (US$ Million)
      • 10.4.12.5. Indonesia Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
    • 10.4.13. Thailand
      • 10.4.13.1. Overview
      • 10.4.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 10.4.13.3. Thailand Market Size and Forecast, By Product Type, 2020 - 2033 (US$ Million)
      • 10.4.13.4. Thailand Market Size and Forecast, By Application, 2020 - 2033 (US$ Million)
      • 10.4.13.5. Thailand Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
    • 10.4.14. Philippines
      • 10.4.14.1. Overview
      • 10.4.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 10.4.14.3. Philippines Market Size and Forecast, By Product Type, 2020 - 2033 (US$ Million)
      • 10.4.14.4. Philippines Market Size and Forecast, By Application, 2020 - 2033 (US$ Million)
      • 10.4.14.5. Philippines Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
    • 10.4.15. Taiwan
      • 10.4.15.1. Overview
      • 10.4.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 10.4.15.3. Taiwan Market Size and Forecast, By Product Type, 2020 - 2033 (US$ Million)
      • 10.4.15.4. Taiwan Market Size and Forecast, By Application, 2020 - 2033 (US$ Million)
      • 10.4.15.5. Taiwan Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
    • 10.4.16. Vietnam
      • 10.4.16.1. Overview
      • 10.4.16.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 10.4.16.3. Vietnam Market Size and Forecast, By Product Type, 2020 - 2033 (US$ Million)
      • 10.4.16.4. Vietnam Market Size and Forecast, By Application, 2020 - 2033 (US$ Million)
      • 10.4.16.5. Vietnam Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
    • 10.4.17. Rest of APAC
      • 10.4.17.1. Overview
      • 10.4.17.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 10.4.17.3. Rest of APAC Market Size and Forecast, By Product Type, 2020 - 2033 (US$ Million)
      • 10.4.17.4. Rest of APAC Market Size and Forecast, By Application, 2020 - 2033 (US$ Million)
      • 10.4.17.5. Rest of APAC Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
  • 10.5. Latin America (LATAM)
    • 10.5.1. Overview
    • 10.5.2. Targeted Radiopharmaceutical Key Manufacturers in Latin America
    • 10.5.3. LATAM Market Size and Forecast, By Country, 2020 - 2033 (US$ Million)
    • 10.5.4. LATAM Market Size and Forecast, By Product Type, 2020 - 2033 (US$ Million)
    • 10.5.5. LATAM Market Size and Forecast, By Application, 2020 - 2033 (US$ Million)
    • 10.5.6. LATAM Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
    • 10.5.7. Brazil
      • 10.5.7.1. Overview
      • 10.5.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 10.5.7.3. Brazil Market Size and Forecast, By Product Type, 2020 - 2033 (US$ Million)
      • 10.5.7.4. Brazil Market Size and Forecast, By Application, 2020 - 2033 (US$ Million)
      • 10.5.7.5. Brazil Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
    • 10.5.8. Mexico
      • 10.5.8.1. Overview
      • 10.5.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 10.5.8.3. Mexico Market Size and Forecast, By Product Type, 2020 - 2033 (US$ Million)
      • 10.5.8.4. Mexico Market Size and Forecast, By Application, 2020 - 2033 (US$ Million)
      • 10.5.8.5. Mexico Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
    • 10.5.9. Argentina
      • 10.5.9.1. Overview
      • 10.5.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 10.5.9.3. Argentina Market Size and Forecast, By Product Type, 2020 - 2033 (US$ Million)
      • 10.5.9.4. Argentina Market Size and Forecast, By Application, 2020 - 2033 (US$ Million)
      • 10.5.9.5. Argentina Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
    • 10.5.10. Colombia
      • 10.5.10.1. Overview
      • 10.5.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 10.5.10.3. Colombia Market Size and Forecast, By Product Type, 2020 - 2033 (US$ Million)
      • 10.5.10.4. Colombia Market Size and Forecast, By Application, 2020 - 2033 (US$ Million)
      • 10.5.10.5. Colombia Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
    • 10.5.11. Rest of LATAM
      • 10.5.11.1. Overview
      • 10.5.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 10.5.11.3. Rest of LATAM Market Size and Forecast, By Product Type, 2020 - 2033 (US$ Million)
      • 10.5.11.4. Rest of LATAM Market Size and Forecast, By Application, 2020 - 2033 (US$ Million)
      • 10.5.11.5. Rest of LATAM Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
  • 10.6. Middle East and Africa (MEA)
    • 10.6.1. Overview
    • 10.6.2. Targeted Radiopharmaceutical Key Manufacturers in Middle East and Africa
    • 10.6.3. MEA Market Size and Forecast, By Country, 2020 - 2033 (US$ Million)
    • 10.6.4. MEA Market Size and Forecast, By Product Type, 2020 - 2033 (US$ Million)
    • 10.6.5. MEA Market Size and Forecast, By Application, 2020 - 2033 (US$ Million)
    • 10.6.6. MEA Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
    • 10.6.7. Saudi Arabia
      • 10.6.7.1. Overview
      • 10.6.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 10.6.7.3. Saudi Arabia Market Size and Forecast, By Product Type, 2020 - 2033 (US$ Million)
      • 10.6.7.4. Saudi Arabia Market Size and Forecast, By Application, 2020 - 2033 (US$ Million)
      • 10.6.7.5. Saudi Arabia Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
    • 10.6.8. UAE
      • 10.6.8.1. Overview
      • 10.6.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 10.6.8.3. UAE Market Size and Forecast, By Product Type, 2020 - 2033 (US$ Million)
      • 10.6.8.4. UAE Market Size and Forecast, By Application, 2020 - 2033 (US$ Million)
      • 10.6.8.5. UAE Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
    • 10.6.9. Israel
      • 10.6.9.1. Overview
      • 10.6.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 10.6.9.3. Israel Market Size and Forecast, By Product Type, 2020 - 2033 (US$ Million)
      • 10.6.9.4. Israel Market Size and Forecast, By Application, 2020 - 2033 (US$ Million)
      • 10.6.9.5. Israel Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
    • 10.6.10. Turkey
      • 10.6.10.1. Overview
      • 10.6.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 10.6.10.3. Turkey Market Size and Forecast, By Product Type, 2020 - 2033 (US$ Million)
      • 10.6.10.4. Turkey Market Size and Forecast, By Application, 2020 - 2033 (US$ Million)
      • 10.6.10.5. Turkey Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
    • 10.6.11. Algeria
      • 10.6.11.1. Overview
      • 10.6.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 10.6.11.3. Algeria Market Size and Forecast, By Product Type, 2020 - 2033 (US$ Million)
      • 10.6.11.4. Algeria Market Size and Forecast, By Application, 2020 - 2033 (US$ Million)
      • 10.6.11.5. Algeria Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
    • 10.6.12. Egypt
      • 10.6.12.1. Overview
      • 10.6.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 10.6.12.3. Egypt Market Size and Forecast, By Product Type, 2020 - 2033 (US$ Million)
      • 10.6.12.4. Egypt Market Size and Forecast, By Application, 2020 - 2033 (US$ Million)
      • 10.6.12.5. Egypt Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
    • 10.6.13. Iran
      • 10.6.13.1. Overview
      • 10.6.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 10.6.13.3. Iran Market Size and Forecast, By Product Type, 2020 - 2033 (US$ Million)
      • 10.6.13.4. Iran Market Size and Forecast, By Application, 2020 - 2033 (US$ Million)
      • 10.6.13.5. Iran Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
    • 10.6.14. Qatar
      • 10.6.14.1. Overview
      • 10.6.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 10.6.14.3. Qatar Market Size and Forecast, By Product Type, 2020 - 2033 (US$ Million)
      • 10.6.14.4. Qatar Market Size and Forecast, By Application, 2020 - 2033 (US$ Million)
      • 10.6.14.5. Qatar Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
    • 10.6.15. Rest of MEA
      • 10.6.15.1. Overview
      • 10.6.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 10.6.15.3. Rest of MEA Market Size and Forecast, By Product Type, 2020 - 2033 (US$ Million)
      • 10.6.15.4. Rest of MEA Market Size and Forecast, By Application, 2020 - 2033 (US$ Million)
      • 10.6.15.5. Rest of MEA Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)

11. Key Vendor Analysis- Targeted Radiopharmaceutical Industry

  • 11.1. Competitive Benchmarking
    • 11.1.1. Competitive Dashboard
    • 11.1.2. Competitive Positioning
  • 11.2. Company Profiles
    • 11.2.1. Novartis AG
    • 11.2.2. Lantheus Holdings, Inc.
    • 11.2.3. Curium Pharma
    • 11.2.4. GE HealthCare
    • 11.2.5. Bayer AG
    • 11.2.6. AstraZeneca plc
    • 11.2.7. Eli Lilly and Company
    • 11.2.8. Bristol Myers Squibb
    • 11.2.9. ITM Isotope Technologies Munich SE
    • 11.2.10. Telix Pharmaceuticals Limited
    • 11.2.11. Bracco Imaging S.p.A.
    • 11.2.12. Clarity Pharmaceuticals Ltd.
    • 11.2.13. Eckert & Ziegler SE
    • 11.2.14. Actinium Pharmaceuticals, Inc.
    • 11.2.15. Evergreen Theragnostics, Inc.
    • 11.2.16. Siemens Healthineers AG
    • 11.2.17. Cardinal Health, Inc.
    • 11.2.18. Boehringer Ingelheim International GmbH
    • 11.2.19. Perspective Therapeutics, Inc.
    • 11.2.20. RadioMedix, Inc.
    • 11.2.21. NorthStar Medical Radioisotopes
    • 11.2.22. Others

12. 360 Degree AnalystView

13. Appendix

  • 13.1. Research Methodology
  • 13.2. References
  • 13.3. Abbreviations
  • 13.4. Disclaimer
  • 13.5. Contact Us
샘플 요청 목록
0 건의 상품을 선택 중
목록 보기
전체삭제
문의
원하시는 정보를
찾아 드릴까요?
문의주시면 필요한 정보를
신속하게 찾아드릴게요.
02-2025-2992
email
문의하기